Liporaxel demonstrated non-inferiority in progression-free survival and superiority in general survival in comparison with intravenous paclitaxel as a second-line remedy for sufferers with superior gastric most cancers.
Amongst sufferers with superior gastric most cancers, second-line remedy of Liporaxel (oral paclitaxel) demonstrated non-inferiority of progression-free survival (PFS) in contrast with the intravenous (IV); nevertheless, Liporaxel confirmed superiority in general survival (OS) versus IV Liporaxel, in response to knowledge from a part 3 medical trial offered in a poster on the 2025 Gastrointestinal Cancers Symposium.
In whole, 268 sufferers obtained the oral answer of Liporaxel and 268 the IV formulation of the agent, between April 22, 2019 and January 31, 2022. The research met non-inferiority standards for PFS, with a median PFS of three.02 months within the oral Liporaxel group in contrast with 2.89 months within the IV group.
Moreover, with a major evaluation cut-off of February 15, 2023, OS confirmed superiority of the Liporaxel oral answer, with a median OS of 9.13 months versus 6.54 within the IV group, exhibiting a 2.59-month enchancment.
Concerning security, the oral answer of Liporaxel was clinically manageable and had a positive security profile versus the IV formulation, supporting Liporaxel oral answer as a second-line remedy choice for gastric most cancers, authors wrote.
Glossary:
Blind impartial overview committee (BIRC): a bunch of impartial medical specialists who overview affected person knowledge from a medical trial with out understanding which remedy group the affected person belongs to, permitting for a much less biased evaluation of the research’s finish factors.
Class 1 most well-liked routine: a remedy plan designated by the Nationwide Complete Most cancers Community tips as probably the most most well-liked choice primarily based on high-level proof.
ECOG efficiency standing: a extensively used medical scale to evaluate a affected person’s practical capability and stage of exercise by evaluating their capability to carry out each day duties and look after themselves.
Intravenous (IV): a medical process that includes inserting a needle or tube right into a vein.
Development-free survival (PFS): a measure in medical trials that signifies the size of time a affected person lives with a illness with out it worsening or progressing.
Non-inferiority: when a brand new remedy just isn’t worse than a regular remedy.
Total survival (OS): the period of time a affected person lives after being recognized with a illness or beginning remedy.
“[Liporaxel] oral answer demonstrated non-inferiority in PFS and superiority in OS in contrast [with Liporaxel] IV, with clinically manageable and favorable security profile,” Dr. Jin Li, of the Division of Medical Oncology, Tongji College Shanghai East Hospital, and co-authors, wrote within the summary describing their poster presentation.
Though IV Liporaxel is a class 1 most well-liked routine within the second-line remedy of gastric most cancers, there stays unmet wants with this remedy strategy together with vehicle-led security danger, very long time injection, premedication or frequent hospital visits. Nonetheless, the oral answer of Liporaxel—the world’s first efficiently developed oral formulation of the agent, in response to the summary—could function an alternative choice to examine this new formulation of the usual of care strategy. Investigators sought to research Liporaxel oral answer versus Liporaxel IV as a second-line monotherapy with the intention to set up non-inferiority in efficacy and comparable security profile for sufferers with gastric most cancers.
Investigators performed this medical trial at 53 facilities in China, evaluating sufferers with unresectable, recurrent or metastatic gastric most cancers which had progressed following remedy with fluoropyrimidine- or fluoropyrimidine plus platinum-based first-line remedy. Eligible individuals have been stratified by gastrectomy, ECOG efficiency standing and prior chemotherapy. Sufferers have been randomly assigned 1:1 to obtain an oral answer of Liporaxel at 200 milligrams per sq. meter (mg/m2) twice each day on days 1, 8 and 15 of a 28-day cycle or IV Liporaxel at 175mg/m2 on day 1 of a 21-day cycle.
The co-primary finish factors of the trial have been PFS assessed by BIRC and OS, in response to the summary.
Therapy-related unwanted effects within the oral administration group had a decrease incidence of all-grade neuropathy versus the IV group (22.3% versus 38.7%); alopecia, fatigue, musculoskeletal and connective tissue issues all occurred at a decrease incidence within the oral group, and no hypersensitivity occurred with out premedication. The authors of the summary famous that the most typical grade 3 or larger treatment-related unwanted effects have been neutrophil rely lower (oral group, 47.9%; IV, 54.5%), white blood cell rely lower (41.5%; 35.3%) and anemia (16.6%; 10.9%). Though grade 5 treatment-related unwanted effects have been uncommon, they’d comparable charges throughout each teams (1.5%; 1.1%).
Reference:
Li J, Huang M, Deng T, et al. Paclitaxel oral answer versus paclitaxel injection as a second-line remedy in superior gastric most cancers: A randomized, open-label, non-inferiority part 3 trial. J Clin Oncol. suppl.442.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
